Pre-made Gavilimomab benchmark antibody (Whole mAb, anti-BSG therapeutic antibody, Anti-5F7/CD147/EMMPRIN/EMPRIN/HAb18G/OK/TCSF Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-BSG therapeutic antibody (Pre-made Gavilimomab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Gavilimomab (also known as ABX-CBL) is a mouse monoclonal antibody intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease. It binds to the antigen CD147.[1] Gavilimomab proved slightly less effective than standard antithymocyte globulin therapy.[2]
| Products Name (INN Index) | Pre-Made Gavilimomab Biosimilar, Whole Mab, Anti-Bsg Antibody: Anti-5F7/CD147/EMMPRIN/EMPRIN/HAb18G/OK/TCSF therapeutic antibody |
|---|---|
| INN Name | gavilimomab |
| Target | BSG |
| Format | Whole mAb |
| Derivation | Mus musculus |
| Species Reactivity | Human |
| CH1 Isotype | IgM – nd |
| VD LC | IgM – nd |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Abgenix (Fremont CA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | BSG |
| Package |
